5520 - Patient’s Usability Test results of a CINV Diary Application For Smartphones

Background

Chemotherapy‐induced nausea and vomiting (CINV) continue to be a clinical problem, particularly in the delayed phase. CINV lack of control worsens the quality of life of patients and it is associated with complications increasing costs for healthcare services. CINV app is a free service addressed to patients treated with emetogenic chemotherapy (CT), empowering patients to report CINV impact in life and relevant information. This study aims to evaluate the usability and acceptability of a smartphone app to improve CINV management in patients receiving CT.

Methods

We used 4‐dimensions test (content, graphic design, navigation and clinical utility) to evaluate APP’s usability and acceptability. Clinical and technical researchers worked together to develop the app’s test. 44 oncology nurses of 33 representative Spanish hospitals were invited to participate (from 31^st January to 5^th April 2019) enrolling a total amount of 116 oncology patients for testing purposes. After using the app for a chemo cycle the patient was asked to fulfil an online usability test.

Results

Described in the table.Table: CN2

Average of patients that agree for each dimension

N = 116 Oncology chemo patients level agreement 83% of patients consider this app useful for them and 86% believe it would help to improve CINV management. 94% of patients would recommend it to other patients.

Conclusions

The CINV app addresses main concerns for patients receiving chemotherapy such as the clinical situation and individual emetic risk of patient or complexity of the prescribed antiemetic regimen and impact of CINV in patients daily life. By soliciting feedback from oncology patients, we ensured that the app was acceptable and beneficial for them although some improvement points were suggested. Reporting of symptoms after CT enhances CINV management, self‐care, and participation without being a burden to patients, indicating that app can be used in clinical practice by patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Vifor Pharma España SL.

Funding

Vifor Pharma España SL.

Disclosure

P. Fernandez: Advisory / Consultancy, advisor activities: Vifor Pharma España. All other authors have declared no conflicts of interest.